Outlook Therapeutics (OTLK)
Market Price (4/7/2026): $0.2091 | Market Cap: $12.6 MilSector: Health Care | Industry: Biotechnology
Outlook Therapeutics (OTLK)
Market Price (4/7/2026): $0.2091Market Cap: $12.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Retinal Disease Treatments, Targeted Therapies, and Biopharmaceutical R&D. | Weak multi-year price returns2Y Excs Rtn is -124%, 3Y Excs Rtn is -163% | Penny stockMkt Price is 0.2 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -59 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -28653% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 234% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 2969% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -27127%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -27127% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 65% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -858% High stock price volatilityVol 12M is 131% Key risksOTLK key risks include [1] its repeated failure to secure FDA approval for its lead drug candidate ONS-5010 and [2] severe financial distress that raises substantial doubt about its ability to continue as a going concern. |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Retinal Disease Treatments, Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -124%, 3Y Excs Rtn is -163% |
| Penny stockMkt Price is 0.2 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -59 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -28653% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 234% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 2969% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -27127%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -27127% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 65% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -858% |
| High stock price volatilityVol 12M is 131% |
| Key risksOTLK key risks include [1] its repeated failure to secure FDA approval for its lead drug candidate ONS-5010 and [2] severe financial distress that raises substantial doubt about its ability to continue as a going concern. |
Qualitative Assessment
AI Analysis | Feedback
Outlook Therapeutics (OTLK) stock has lost about 85% since 12/31/2025 because of the following key factors:
1. FDA issued a Complete Response Letter (CRL) for ONS-5010.
On December 30, 2025, Outlook Therapeutics received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for wet Age-related Macular Degeneration (AMD). The CRL cited a lack of substantial evidence of effectiveness and requested additional confirmatory evidence, leading to a significant negative market reaction.
2. Significant increase in net loss in Q1 FY2026.
For the fiscal first quarter ended December 31, 2025, reported on February 17, 2026, Outlook Therapeutics announced a net loss attributable to common stockholders of $23.1 million, or $0.38 per basic and diluted share. This represented a substantial negative shift from a net income of $17.4 million, or $0.72 per basic and diluted share, during the same period in the prior year. The adjusted net loss of $0.22 per share also missed analysts' expectations by 29.41%.
Show more
1. FDA issued a Complete Response Letter (CRL) for ONS-5010.
On December 30, 2025, Outlook Therapeutics received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for wet Age-related Macular Degeneration (AMD). The CRL cited a lack of substantial evidence of effectiveness and requested additional confirmatory evidence, leading to a significant negative market reaction.
2. Significant increase in net loss in Q1 FY2026.
For the fiscal first quarter ended December 31, 2025, reported on February 17, 2026, Outlook Therapeutics announced a net loss attributable to common stockholders of $23.1 million, or $0.38 per basic and diluted share. This represented a substantial negative shift from a net income of $17.4 million, or $0.72 per basic and diluted share, during the same period in the prior year. The adjusted net loss of $0.22 per share also missed analysts' expectations by 29.41%.
Show more
Stock Movement Drivers
Fundamental Drivers
The -87.3% change in OTLK stock from 12/31/2025 to 4/6/2026 was primarily driven by a -85.4% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.58 | 0.20 | -87.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -85.4% |
| P/S Multiple | 52.8 | 58.7 | 11.3% |
| Shares Outstanding (Mil) | 47 | 60 | -21.6% |
| Cumulative Contribution | -87.3% |
Market Drivers
12/31/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| OTLK | -87.3% | |
| Market (SPY) | -5.4% | 6.9% |
| Sector (XLV) | -5.5% | 5.9% |
Fundamental Drivers
The -81.1% change in OTLK stock from 9/30/2025 to 4/6/2026 was primarily driven by a -86.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.06 | 0.20 | -81.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 0 | -86.3% |
| P/S Multiple | 26.0 | 58.7 | 125.6% |
| Shares Outstanding (Mil) | 37 | 60 | -38.6% |
| Cumulative Contribution | -81.1% |
Market Drivers
9/30/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| OTLK | -81.1% | |
| Market (SPY) | -2.9% | 8.4% |
| Sector (XLV) | 5.6% | 2.3% |
Fundamental Drivers
The -83.6% change in OTLK stock from 3/31/2025 to 4/6/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.22 | 0.20 | -83.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 58.7 | |
| Shares Outstanding (Mil) | 24 | 60 | -59.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| OTLK | -83.6% | |
| Market (SPY) | 16.3% | 9.8% |
| Sector (XLV) | 1.6% | 4.8% |
Fundamental Drivers
The -99.1% change in OTLK stock from 3/31/2023 to 4/6/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.80 | 0.20 | -99.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 58.7 | |
| Shares Outstanding (Mil) | 11 | 60 | -81.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/6/2026| Return | Correlation | |
|---|---|---|
| OTLK | -99.1% | |
| Market (SPY) | 63.3% | 9.6% |
| Sector (XLV) | 18.3% | 5.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OTLK Return | 5% | -21% | -64% | -76% | -16% | -86% | -99% |
| Peers Return | 10% | -24% | -24% | 28% | 45% | 18% | 39% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -4% | 75% |
Monthly Win Rates [3] | |||||||
| OTLK Win Rate | 42% | 50% | 33% | 42% | 58% | 25% | |
| Peers Win Rate | 57% | 45% | 47% | 45% | 52% | 65% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OTLK Max Drawdown | -28% | -36% | -81% | -82% | -55% | -87% | |
| Peers Max Drawdown | -20% | -40% | -46% | -29% | -35% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: REGN, AMGN, PFE, CHRS, KOD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/6/2026 (YTD)
How Low Can It Go
| Event | OTLK | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.8% | -25.4% |
| % Gain to Breakeven | 1525.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -61.9% | -33.9% |
| % Gain to Breakeven | 162.3% | 51.3% |
| Time to Breakeven | 146 days | 148 days |
| 2018 Correction | ||
| % Loss | -98.2% | -19.8% |
| % Gain to Breakeven | 5605.6% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to REGN, AMGN, PFE, CHRS, KOD
In The Past
Outlook Therapeutics's stock fell -93.8% during the 2022 Inflation Shock from a high on 2/8/2021. A -93.8% loss requires a 1525.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Outlook Therapeutics (OTLK)
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
AI Analysis | Feedback
Outlook Therapeutics is a specialized biotech focused on eye disease treatments, aiming to become a significant player in conditions like wet macular degeneration, similar to how Regeneron developed Eylea for that very market.
Outlook Therapeutics is a biotech company specializing exclusively in developing drugs for eye diseases, much like how Gilead Sciences gained prominence by focusing intensely on breakthrough therapies for infectious diseases.
AI Analysis | Feedback
- ONS-5010: An ophthalmic formulation of bevacizumab in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
AI Analysis | Feedback
Outlook Therapeutics (OTLK) is a late clinical-stage biopharmaceutical company with its lead product candidate, ONS-5010, currently in Phase-III clinical trials. As such, the company is not yet selling its product commercially and therefore does not have major customers in the traditional sense. Its focus is on the development and regulatory approval of ONS-5010 for ophthalmic indications. Should ONS-5010 receive regulatory approval and be commercialized, Outlook Therapeutics' customers would likely be:- Pharmaceutical distributors and wholesalers that facilitate the supply of medicines to pharmacies, hospitals, and clinics.
- Hospitals, ophthalmology clinics, and other healthcare providers that would administer the treatment to patients.
- Potentially, specialty pharmacies that dispense complex or high-cost medications directly to patients.
AI Analysis | Feedback
- Wacker Biotech GmbH (subsidiary of Evonik Industries AG - EVK)
- Avara Pharmaceutical Services, Inc.
AI Analysis | Feedback
Following is the management team of Outlook Therapeutics (OTLK):Bob Jahr
Chief Executive Officer Mr. Jahr was appointed Chief Executive Officer in July 2025. He brings over 20 years of experience in the biopharmaceutical industry, building and leading commercial teams across various therapeutic areas including rare disease, oncology, hematology, autoimmunology, neuroscience, cardiovascular, and inflammation. Before joining Outlook Therapeutics, Mr. Jahr served as the Chief Commercial Officer for Sobi North America (NA), where he was responsible for commercial strategy, planning, and execution, including all marketing, sales, operations, and market access activities. During his time at Sobi NA, he led immunology and hematology franchises and three global development asset teams. Prior to Sobi NA, he was General Manager & Vice President Head of International Markets at UCB Pharma SA (UCB), managing the company's portfolio in markets such as China, Japan, Brazil, Australia, Canada, the Middle East, and Latin America. He also held leadership roles in sales, marketing, operations, payer strategy, and market access at Amgen.Lawrence A. Kenyon
Executive Vice President, Chief Financial Officer, Treasurer, Secretary and Director Mr. Kenyon has served as the Company's Chief Financial Officer and Secretary since September 2015. He has also been a member of Outlook Therapeutics' Board of Directors since August 2018. From December 2024 to July 2025, he served as interim CEO and previously held the roles of President and CEO from August 2018 to July 2021. Prior to that, from February 2014 to September 2015, Mr. Kenyon was the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company, where he also served as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, he served as Interim President & Chief Executive Officer, Chief Financial Officer, and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company. Before that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and later Chief Financial Officer of Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company.Joel Prieve
Senior Vice President of Licensing and M&A Mr. Prieve is the Senior Vice President of Licensing and M&A at Outlook Therapeutics.Dr. Jennifer M. Kissner Ph.D.
Senior Vice President of Clinical Development and Regulatory Affairs Dr. Kissner serves as the Senior Vice President of Clinical Development and Regulatory Affairs for Outlook Therapeutics.AI Analysis | Feedback
The key risks to Outlook Therapeutics' business are as follows:- Regulatory Approval Uncertainty for ONS-5010: Outlook Therapeutics faces substantial risk regarding the regulatory approval of its lead product candidate, ONS-5010 (LYTENAVA), for wet age-related macular degeneration (wet AMD) in the United States. The U.S. Food and Drug Administration (FDA) has issued multiple Complete Response Letters (CRLs) for ONS-5010's Biologics License Application (BLA), most recently citing a "lack of substantial evidence of effectiveness." While one pivotal study (NORSE TWO) demonstrated efficacy, another confirmatory trial (NORSE EIGHT) failed to meet its primary efficacy endpoint. The FDA continues to request additional confirmatory evidence without specifying the acceptable format, leading to significant uncertainty regarding the approval pathway and timing.
- Significant Financial Challenges: The company is facing severe financial difficulties, characterized by negative operating and net margins, substantial operating losses, and negative cash flow. Its total liabilities outweigh total assets, and a distressed Altman Z-Score indicates a high risk of bankruptcy. The ongoing delays in regulatory approval for ONS-5010 exacerbate these financial pressures, as the company incurs considerable research and development and operational costs without a significant revenue stream from its primary product in the U.S. market.
- Reliance on Third-Party Manufacturing: Outlook Therapeutics is highly dependent on third-party manufacturers, notably FUJIFILM Diosynth Biotechnologies, for the production and supply of its drug candidates, including ONS-5010. This reliance exposes the company to risks such as potential supply interruptions, quality control issues, and challenges with regulatory compliance. Any disruptions or breaches in these manufacturing agreements could lead to costly delays in clinical trials and commercialization efforts, negatively impacting business operations, revenue, and gross margins.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for Outlook Therapeutics' main product candidate, ONS-5010, which targets wet age-related macular degeneration (wet AMD) and other retina diseases, are substantial globally and within key regions.
Wet Age-Related Macular Degeneration (wet AMD)
- Globally, the wet AMD market size was estimated at USD 10.6 billion in 2025 and is projected to grow to USD 16.7 billion by 2032.
- In the 7 Major Markets (7MM), which include the U.S., Germany, France, Italy, Spain, the United Kingdom, and Japan, the wet AMD market was valued at approximately USD 7.783 billion in 2023.
- Specifically for the U.S. market, the wet AMD market size was approximately USD 2.599 billion in 2023 and is expected to increase at a Compound Annual Growth Rate (CAGR) of 6.6% by 2034.
Broader Retinal Disease Therapeutics Market (including wet AMD and other retina diseases)
- The global retinal disease therapeutics market was valued at USD 12.86 billion in 2024 and is anticipated to grow to USD 27.93 billion by 2033, with a CAGR of 9%.
- The U.S. retinal disorder treatment market is projected to expand from USD 7.1 billion in 2024 to USD 13.1 billion by 2034.
- Outlook Therapeutics itself has stated that ONS-5010 has the potential to address a USD 9.1 billion anti-VEGF market. The macular degeneration segment holds the largest share within the overall retinal disorder treatment market.
AI Analysis | Feedback
Outlook Therapeutics (OTLK) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily centered around its lead product candidate, ONS-5010 (branded as LYTENAVA).
- Growing Sales and Market Uptake in Existing European Markets: LYTENAVA (bevacizumab gamma) has already received marketing authorization from the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of wet age-related macular degeneration (wet AMD). Commercialization commenced in June 2025, with initial sales in Germany and the UK. The company has observed strong positive momentum, evidenced by a doubling of Lytenava unit sales in the UK and Germany in the first quarter of 2026 compared to the prior quarter, indicating increasing market uptake. Continued growth in these initial markets is expected to contribute to revenue.
- Geographic Expansion into Additional European Markets: Beyond the UK and Germany, Outlook Therapeutics plans to expand the launch of LYTENAVA into other key European markets. The anticipated launch in additional EU markets, such as France, Italy, and Spain, by 2027 is expected to further drive revenue growth. The company also continues to identify potential partners for additional expansion outside the U.S., with efforts to expand into Austria and the Netherlands already underway.
- Potential U.S. FDA Approval and Commercial Launch of ONS-5010: While ONS-5010 has faced multiple Complete Response Letters (CRLs) from the FDA regarding its Biologics License Application (BLA) for wet AMD, most recently on December 31, 2025, Outlook Therapeutics remains committed to securing U.S. approval. The company views the U.S. as the largest addressable market for anti-VEGF therapies, with an estimated annual revenue of approximately $6.7 billion across wet AMD, DME, and RVO treatments. An eventual FDA approval would allow ONS-5010 (Lytenava) to become the first officially sanctioned ophthalmic bevacizumab in the U.S., unlocking significant revenue potential and providing 12 years of regulatory exclusivity.
- Conversion from Off-Label Bevacizumab Use: If ONS-5010 receives FDA approval, it is poised to capture a considerable patient share from the current off-label use of Avastin (bevacizumab) for wet AMD. As an FDA-approved, on-label formulation specifically for ophthalmic use, ONS-5010 offers a safer and more consistent alternative to compounded Avastin, potentially attracting both physicians and patients. Analysts anticipate substantial long-term growth prospects from converting off-label bevacizumab use to an approved product.
AI Analysis | Feedback
Share Issuance
- The number of shares outstanding for Outlook Therapeutics increased by 105.06% in one year.
- The company executed a 1-for-20 reverse stock split on March 14, 2024.
- Institutional investors hold a total of 6,902,013 shares in the company.
Inbound Investments
- Sphera-affiliated investment entities reported beneficial ownership of 3,153,856 warrants as of December 16, 2025, each exercisable into one share of common stock, representing 4.69% of the class.
- In February 2026, Outlook Therapeutics expanded its European presence through an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland.
Capital Expenditures
- Outlook Therapeutics reported $0.00 in capital expenditures during the last 12 months.
- The company's capital allocation is primarily focused on research and development for its lead product candidate, ONS-5010, for ophthalmic indications, which are generally expensed rather than capitalized.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Outlook Therapeutics Earnings Notes | 12/16/2025 | |
| How Low Can Outlook Therapeutics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to OTLK.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 33.41 |
| Mkt Cap | 40.4 |
| Rev LTM | 7,193 |
| Op Inc LTM | 1,822 |
| FCF LTM | 1,855 |
| FCF 3Y Avg | 1,800 |
| CFO LTM | 2,462 |
| CFO 3Y Avg | 2,304 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.5% |
| Rev Chg 3Y Avg | 1.5% |
| Rev Chg Q | 5.5% |
| QoQ Delta Rev Chg LTM | 0.7% |
| Op Mgn LTM | 24.7% |
| Op Mgn 3Y Avg | 22.2% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 18.7% |
| CFO/Rev 3Y Avg | 24.1% |
| FCF/Rev LTM | 14.5% |
| FCF/Rev 3Y Avg | 19.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 40.4 |
| P/S | 5.0 |
| P/EBIT | 7.4 |
| P/E | 9.3 |
| P/CFO | 6.7 |
| Total Yield | 6.6% |
| Dividend Yield | 0.2% |
| FCF Yield 3Y Avg | -21.3% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.4% |
| 3M Rtn | 10.0% |
| 6M Rtn | 13.5% |
| 12M Rtn | 31.9% |
| 3Y Rtn | -13.5% |
| 1M Excs Rtn | 0.5% |
| 3M Excs Rtn | 12.4% |
| 6M Excs Rtn | 13.1% |
| 12M Excs Rtn | 5.2% |
| 3Y Excs Rtn | -75.8% |
Price Behavior
Price Behavior
| Market Price | $0.20 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/14/2016 | |
| Distance from 52W High | -93.2% | |
| 50 Days | 200 Days | |
| DMA Price | $0.38 | $1.27 |
| DMA Trend | down | down |
| Distance from DMA | -47.7% | -84.2% |
| 3M | 1YR | |
| Volatility | 117.9% | 131.8% |
| Downside Capture | 2.48 | 1.04 |
| Upside Capture | -44.93 | -65.31 |
| Correlation (SPY) | 14.5% | 9.4% |
OTLK Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.97 | 2.07 | 1.13 | 0.93 | 0.67 | 0.83 |
| Up Beta | -12.64 | 1.51 | 6.55 | 3.03 | 0.93 | 0.86 |
| Down Beta | -5.29 | 0.02 | 1.25 | 1.65 | 0.49 | 0.91 |
| Up Capture | 181% | 83% | -404% | -134% | -33% | -5% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 16 | 22 | 53 | 116 | 342 |
| Down Capture | 534% | 358% | 340% | 161% | 121% | 110% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 14 | 26 | 41 | 71 | 125 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OTLK | |
|---|---|---|---|---|
| OTLK | -85.4% | 131.0% | -0.67 | - |
| Sector ETF (XLV) | 2.8% | 17.6% | 0.00 | 5.2% |
| Equity (SPY) | 15.3% | 19.0% | 0.64 | 10.1% |
| Gold (GLD) | 49.6% | 28.0% | 1.44 | 2.6% |
| Commodities (DBC) | 15.5% | 17.7% | 0.74 | 3.3% |
| Real Estate (VNQ) | 3.1% | 16.5% | 0.01 | 8.8% |
| Bitcoin (BTCUSD) | -19.0% | 44.0% | -0.35 | 7.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OTLK | |
|---|---|---|---|---|
| OTLK | -66.1% | 110.5% | -0.29 | - |
| Sector ETF (XLV) | 6.1% | 14.5% | 0.24 | 9.7% |
| Equity (SPY) | 11.7% | 17.0% | 0.53 | 15.1% |
| Gold (GLD) | 21.8% | 17.8% | 1.01 | 5.3% |
| Commodities (DBC) | 11.6% | 18.8% | 0.50 | 5.5% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.09 | 10.7% |
| Bitcoin (BTCUSD) | 3.0% | 56.5% | 0.27 | 7.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OTLK | |
|---|---|---|---|---|
| OTLK | -56.0% | 120.1% | -0.08 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 7.5% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 11.4% |
| Gold (GLD) | 14.0% | 15.9% | 0.73 | 2.8% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 5.2% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 8.6% |
| Bitcoin (BTCUSD) | 65.9% | 66.9% | 1.05 | 4.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/19/2025 | -2.9% | -12.1% | -75.6% |
| 8/14/2025 | -3.7% | -0.8% | -56.8% |
| 5/15/2025 | 4.5% | -2.1% | 5.7% |
| 12/27/2024 | 18.2% | 31.8% | 17.1% |
| 8/14/2024 | -5.3% | -8.4% | -16.3% |
| 5/15/2024 | -1.3% | 7.7% | 3.2% |
| 12/22/2023 | 5.4% | -7.1% | 2.8% |
| 8/14/2023 | -1.3% | -12.7% | -85.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 10 |
| # Negative | 9 | 9 | 8 |
| Median Positive | 5.4% | 7.7% | 9.8% |
| Median Negative | -2.9% | -7.1% | -43.7% |
| Max Positive | 18.2% | 35.8% | 61.6% |
| Max Negative | -10.3% | -19.2% | -85.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 12/19/2025 | 10-K |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-Q |
| 09/30/2024 | 12/27/2024 | 10-K |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 12/22/2023 | 10-K |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 12/29/2022 | 10-K |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.